Rockland Trust Co. Reduces Holdings in Johnson & Johnson $JNJ

Rockland Trust Co. lessened its position in Johnson & Johnson (NYSE:JNJ) by 4.6% in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 102,425 shares of the company’s stock after selling 4,972 shares during the quarter. Rockland Trust Co.’s holdings in Johnson & Johnson were worth $18,992,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors have also added to or reduced their stakes in JNJ. Clayton Financial Group LLC purchased a new stake in shares of Johnson & Johnson in the third quarter worth $28,000. Evolution Wealth Management Inc. purchased a new stake in Johnson & Johnson during the 2nd quarter valued at $27,000. Semmax Financial Advisors Inc. increased its holdings in shares of Johnson & Johnson by 55.0% in the 2nd quarter. Semmax Financial Advisors Inc. now owns 203 shares of the company’s stock worth $31,000 after purchasing an additional 72 shares in the last quarter. Compass Financial Services Inc raised its stake in shares of Johnson & Johnson by 707.1% in the third quarter. Compass Financial Services Inc now owns 226 shares of the company’s stock worth $42,000 after purchasing an additional 198 shares during the last quarter. Finally, Signature Resources Capital Management LLC increased its holdings in Johnson & Johnson by 262.9% in the 3rd quarter. Signature Resources Capital Management LLC now owns 254 shares of the company’s stock worth $47,000 after buying an additional 184 shares in the last quarter. Institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Trading Down 0.6%

Shares of JNJ stock opened at $238.62 on Tuesday. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.80 and a current ratio of 1.07. The stock has a fifty day simple moving average of $214.20 and a two-hundred day simple moving average of $194.70. The firm has a market capitalization of $574.90 billion, a PE ratio of 21.59, a PEG ratio of 2.33 and a beta of 0.35. Johnson & Johnson has a 52-week low of $141.50 and a 52-week high of $240.93.

Johnson & Johnson (NYSE:JNJ) last released its earnings results on Wednesday, January 21st. The company reported $2.46 earnings per share (EPS) for the quarter, hitting the consensus estimate of $2.46. Johnson & Johnson had a return on equity of 33.34% and a net margin of 28.46%.The firm had revenue of $24.56 billion during the quarter, compared to analysts’ expectations of $24.14 billion. During the same quarter last year, the business posted $2.04 earnings per share. The firm’s revenue was up 9.1% on a year-over-year basis. Johnson & Johnson has set its FY 2026 guidance at 11.430-11.630 EPS. On average, analysts predict that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, March 10th. Investors of record on Tuesday, February 24th will be paid a dividend of $1.30 per share. This represents a $5.20 annualized dividend and a yield of 2.2%. The ex-dividend date of this dividend is Tuesday, February 24th. Johnson & Johnson’s dividend payout ratio (DPR) is presently 47.06%.

Wall Street Analyst Weigh In

A number of equities research analysts have commented on JNJ shares. Wolfe Research lifted their target price on shares of Johnson & Johnson from $225.00 to $240.00 and gave the stock an “outperform” rating in a research report on Monday, January 5th. Freedom Capital cut shares of Johnson & Johnson from a “strong-buy” rating to a “hold” rating in a report on Friday, January 16th. Morgan Stanley set a $262.00 price target on shares of Johnson & Johnson and gave the stock an “overweight” rating in a research report on Wednesday, January 28th. Daiwa Securities Group boosted their price objective on shares of Johnson & Johnson from $203.00 to $237.00 and gave the company an “outperform” rating in a research report on Thursday, January 29th. Finally, Johnson Rice set a $190.00 target price on Johnson & Johnson and gave the company a “hold” rating in a research report on Wednesday, October 22nd. One research analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and eight have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $233.73.

Johnson & Johnson Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.